• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, August 25, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

African subterranean animal exhibits ‘extraordinary’ cancer resistance

Bioengineer by Bioengineer
June 16, 2016
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Naked mole-rats (NMR) are the longest-living rodent species and exhibit ‘extraordinary’ resistance to cancer. Mole-rats live up to 30 years, 10 times longer than mice, and captured colonies almost never show any type of cancer. Understanding these animals’ anti-cancer mechanisms may help advance human treatment in the future, according to a collaborative research team from Hokkaido University and Keio University in Japan.

The research team took skin fibroblast tissue from adult mole-rats and reprogrammed the cells to revert to pluripotent stem cells. These are called induced pluripotent stem cells (iPSCs) and, like embryonic stem cells, are capable of becoming any type of tissue in the body. However, these stem cells can also form tumours called teratomas when transplanted back into the animals.

When the mole-rats’ iPSCs were inserted into the testes of mice with extremely weak immune systems, the team discovered that they didn’t form tumours in contrast to human iPSCs and mouse iPSCs. Upon further investigation, they found that a tumour-suppressor gene called alternative reading frame (ARF), which is normally suppressed in mouse and human iPSCs, remained active in the mole-rat iPSCs.

The team also found that ERAS, a tumorigenic gene expressed in mouse embryonic stem cells and iPSCs, was mutated and dysfunctional in the mole-rat iPSCs. When the researchers disabled the ARF gene, forced the expression of the mouse ERAS gene in the mole-rat iPSCs, and then inserted them into the mice, the mice grew large tumours.

When researchers suppressed the ARF gene in mole-rat cells during the reprogramming process to iPSCs, the cells stopped proliferation with sign of cellular senescence, while the opposite happens with mouse cells. Researchers theorize that this further helps protect the naked mole-rat by reducing the chance for tumour formation. They call this ARF suppression-induced senescence (ASIS) and it appears to be unique to the naked mole-rat.

These findings could help researchers figure out how human iPSCs can be used for treating patients without forming tumours, which is one of the major challenges associated with undifferentiated iPSCs. “Further research into the detailed mechanisms underlying ASIS in naked mole-rats may shed new light on cancer resistance in the mole-rats and contribute to the generation of non-tumorigenic human-iPSCs, enabling safer cell-based therapeutics,” said Kyoko Miura, an assistant professor at Hokkaido University.

###

Media Contact

Naoki Namba
[email protected]
81-117-068-034
@hokkaido_uni

http://www.oia.hokudai.ac.jp/

The post African subterranean animal exhibits ‘extraordinary’ cancer resistance appeared first on Scienmag.

Share12Tweet7Share2ShareShareShare1

Related Posts

New Trial Tests Venetoclax, Ibrutinib Combo Against Mantle Cell Lymphoma

New Trial Tests Venetoclax, Ibrutinib Combo Against Mantle Cell Lymphoma

August 25, 2025
Immune Signatures Forecast Gastric Cancer Treatment Response

Immune Signatures Forecast Gastric Cancer Treatment Response

August 25, 2025

Boosting Immunotherapy in Advanced Prostate Cancer Treatment

August 25, 2025

Gemcitabine, Cisplatin, Durvalumab for Biliary Cancer: Insights

August 24, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    138 shares
    Share 55 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Transforming Spin Loss into Energy: Pioneering Key Technology for Ultra-Low Power Next-Generation Information Devices

New Guidelines Present Strategies to Support Tobacco Cessation Efforts

New Trial Tests Venetoclax, Ibrutinib Combo Against Mantle Cell Lymphoma

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.